India, July 17 -- The national drugs regulator has approved Novo Nordisk's weight-loss drug, Wegovy, for use in adults living with fatty liver disease, the company announced on Friday.

"The Central Drugs Standard Control Organization (CDSCO) has approved a new indication for Wegovy (semaglutide injection 2.4 mg), making it the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity," said Denmark based global health care company in a statement.

MASH is a liver disease that develops due to excess fat build-up in the liver, c...